Injection Site Reactions Tesamorelin treatment may cause injection site reactions, including injection site erythema, pruritus, pain, irritation, and bruising
GLP-1 medications, such as semaglutide (Wegovy, Ozempic) and tirzepatide (Mounjaro, Zepbound), were originally developed for type 2 diabetes and later approved for chronic weight management at full therapeutic doses
These effects resolve with dose reduction but indicate levels beyond physiological optimization
PMID 15632295
We ask that you provide the name of the group and Client ID in your email
Without this physiological support, the bodys natural metabolic drive often attempts to return to its previous set point weight, leading to the recurrence of cravings and increased caloric intake